| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 52 | 2024 | 149 | 13.900 |
Why?
|
| Lung | 47 | 2024 | 446 | 6.860 |
Why?
|
| Respiratory Mucosa | 24 | 2021 | 43 | 5.580 |
Why?
|
| Smoking | 35 | 2023 | 940 | 5.490 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 18 | 2023 | 152 | 5.340 |
Why?
|
| Smoke | 18 | 2022 | 40 | 5.090 |
Why?
|
| Epithelial Cells | 27 | 2023 | 384 | 5.040 |
Why?
|
| Pulmonary Emphysema | 10 | 2024 | 12 | 3.530 |
Why?
|
| Bronchitis, Chronic | 6 | 2023 | 15 | 3.490 |
Why?
|
| Pneumonia | 10 | 2023 | 54 | 3.280 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2017 | 190 | 3.070 |
Why?
|
| Forced Expiratory Volume | 19 | 2024 | 70 | 2.990 |
Why?
|
| Mitochondrial Proteins | 8 | 2023 | 107 | 2.430 |
Why?
|
| Lipopolysaccharides | 15 | 2018 | 220 | 2.260 |
Why?
|
| Asthma | 15 | 2022 | 380 | 2.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2022 | 15 | 2.080 |
Why?
|
| Health Status | 5 | 2018 | 380 | 2.050 |
Why?
|
| Emphysema | 3 | 2024 | 6 | 2.020 |
Why?
|
| Allergens | 13 | 2021 | 63 | 2.000 |
Why?
|
| Hyperplasia | 13 | 2021 | 38 | 1.920 |
Why?
|
| Animals | 81 | 2024 | 15081 | 1.890 |
Why?
|
| Inflammation | 15 | 2023 | 618 | 1.880 |
Why?
|
| Wood | 8 | 2022 | 16 | 1.880 |
Why?
|
| Apoptosis Regulatory Proteins | 11 | 2023 | 147 | 1.870 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 213 | 1.750 |
Why?
|
| Mice, Inbred C57BL | 26 | 2024 | 1609 | 1.720 |
Why?
|
| Air Pollutants | 6 | 2022 | 94 | 1.700 |
Why?
|
| Apoptosis | 21 | 2023 | 1398 | 1.660 |
Why?
|
| Interleukin-13 | 5 | 2018 | 19 | 1.660 |
Why?
|
| Mice | 48 | 2024 | 5913 | 1.650 |
Why?
|
| Humans | 107 | 2024 | 37093 | 1.640 |
Why?
|
| Interferon-gamma | 10 | 2018 | 250 | 1.620 |
Why?
|
| Goblet Cells | 7 | 2016 | 11 | 1.550 |
Why?
|
| Bronchi | 12 | 2021 | 46 | 1.510 |
Why?
|
| Sputum | 6 | 2021 | 17 | 1.500 |
Why?
|
| Membrane Proteins | 9 | 2020 | 517 | 1.430 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 358 | 1.380 |
Why?
|
| Autophagy | 4 | 2013 | 116 | 1.370 |
Why?
|
| Bronchoalveolar Lavage Fluid | 19 | 2018 | 56 | 1.320 |
Why?
|
| Influenza A virus | 3 | 2023 | 27 | 1.320 |
Why?
|
| DNA Methylation | 9 | 2020 | 325 | 1.310 |
Why?
|
| Male | 67 | 2024 | 20025 | 1.300 |
Why?
|
| Hypersensitivity | 3 | 2018 | 30 | 1.250 |
Why?
|
| Mucus | 8 | 2016 | 15 | 1.190 |
Why?
|
| Spirometry | 6 | 2023 | 33 | 1.170 |
Why?
|
| Orthomyxoviridae Infections | 3 | 2016 | 12 | 1.150 |
Why?
|
| Gene Expression | 9 | 2022 | 674 | 1.150 |
Why?
|
| Volatile Organic Compounds | 2 | 2022 | 17 | 1.070 |
Why?
|
| Middle Aged | 38 | 2024 | 10129 | 1.060 |
Why?
|
| Metaplasia | 14 | 2016 | 37 | 1.060 |
Why?
|
| Pneumonia, Viral | 2 | 2018 | 76 | 1.050 |
Why?
|
| Female | 58 | 2024 | 20969 | 1.030 |
Why?
|
| bcl-2-Associated X Protein | 5 | 2008 | 77 | 1.010 |
Why?
|
| Uteroglobin | 5 | 2018 | 8 | 1.000 |
Why?
|
| Aged | 32 | 2024 | 6741 | 0.980 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2023 | 114 | 0.950 |
Why?
|
| Quality of Life | 3 | 2022 | 481 | 0.950 |
Why?
|
| Hexosyltransferases | 1 | 2023 | 5 | 0.940 |
Why?
|
| Proteomics | 3 | 2023 | 325 | 0.920 |
Why?
|
| Cytokines | 11 | 2023 | 602 | 0.900 |
Why?
|
| Vital Capacity | 7 | 2024 | 39 | 0.900 |
Why?
|
| Particulate Matter | 2 | 2022 | 51 | 0.880 |
Why?
|
| Mucin 5AC | 6 | 2018 | 6 | 0.870 |
Why?
|
| Weight Gain | 2 | 2014 | 136 | 0.870 |
Why?
|
| Mice, Knockout | 16 | 2020 | 933 | 0.870 |
Why?
|
| Mucins | 5 | 2022 | 35 | 0.860 |
Why?
|
| Endoplasmic Reticulum | 2 | 2017 | 105 | 0.860 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2013 | 173 | 0.850 |
Why?
|
| Disease Models, Animal | 15 | 2024 | 1371 | 0.840 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2022 | 8 | 0.830 |
Why?
|
| Airway Remodeling | 3 | 2018 | 11 | 0.830 |
Why?
|
| Neutrophils | 8 | 2019 | 131 | 0.820 |
Why?
|
| Casein Kinase II | 1 | 2021 | 15 | 0.810 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2012 | 70 | 0.810 |
Why?
|
| Mucous Membrane | 5 | 2011 | 34 | 0.780 |
Why?
|
| Pyroglyphidae | 2 | 2018 | 4 | 0.760 |
Why?
|
| Endothelial Cells | 1 | 2023 | 308 | 0.730 |
Why?
|
| Homeostasis | 2 | 2020 | 188 | 0.730 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 1015 | 0.720 |
Why?
|
| Risk Factors | 17 | 2022 | 3562 | 0.720 |
Why?
|
| Lysosomes | 1 | 2020 | 91 | 0.720 |
Why?
|
| Promoter Regions, Genetic | 7 | 2015 | 515 | 0.720 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 106 | 0.720 |
Why?
|
| Influenza, Human | 2 | 2023 | 83 | 0.710 |
Why?
|
| Genes, bcl-2 | 4 | 2011 | 6 | 0.700 |
Why?
|
| Matrix Metalloproteinase 9 | 4 | 2019 | 90 | 0.690 |
Why?
|
| Adult | 29 | 2024 | 11712 | 0.680 |
Why?
|
| Tobacco Smoke Pollution | 5 | 2021 | 48 | 0.660 |
Why?
|
| Rats, Inbred F344 | 10 | 2016 | 245 | 0.650 |
Why?
|
| Genome-Wide Association Study | 9 | 2023 | 333 | 0.640 |
Why?
|
| New Mexico | 7 | 2018 | 31 | 0.640 |
Why?
|
| Cough | 1 | 2018 | 18 | 0.630 |
Why?
|
| Cell Death | 5 | 2016 | 267 | 0.630 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 105 | 0.630 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 11 | 0.630 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2016 | 6 | 0.630 |
Why?
|
| Nasal Septum | 1 | 2018 | 5 | 0.630 |
Why?
|
| Interleukin-9 | 2 | 2008 | 6 | 0.630 |
Why?
|
| Interleukin-17 | 1 | 2018 | 53 | 0.630 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2019 | 767 | 0.620 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2017 | 4 | 0.620 |
Why?
|
| Ovalbumin | 9 | 2017 | 47 | 0.620 |
Why?
|
| RNA | 1 | 2020 | 241 | 0.620 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2006 | 239 | 0.610 |
Why?
|
| Mitochondria | 2 | 2020 | 487 | 0.600 |
Why?
|
| GATA4 Transcription Factor | 2 | 2014 | 6 | 0.580 |
Why?
|
| Caspase 3 | 3 | 2016 | 207 | 0.580 |
Why?
|
| Rats | 17 | 2018 | 3483 | 0.580 |
Why?
|
| Immunologic Memory | 1 | 2016 | 38 | 0.570 |
Why?
|
| Poly I-C | 1 | 2016 | 7 | 0.560 |
Why?
|
| Immunity, Mucosal | 1 | 2016 | 47 | 0.560 |
Why?
|
| Cells, Cultured | 10 | 2020 | 1518 | 0.550 |
Why?
|
| RNA, Messenger | 6 | 2021 | 1207 | 0.550 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2016 | 103 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2019 | 628 | 0.540 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2016 | 99 | 0.540 |
Why?
|
| Time Factors | 7 | 2016 | 1742 | 0.530 |
Why?
|
| Obesity | 2 | 2014 | 1067 | 0.530 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 2721 | 0.510 |
Why?
|
| Lung Diseases | 2 | 2014 | 61 | 0.510 |
Why?
|
| Cohort Studies | 10 | 2024 | 1492 | 0.500 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2014 | 16 | 0.500 |
Why?
|
| Genes, p53 | 1 | 2014 | 25 | 0.500 |
Why?
|
| Viral Proteins | 1 | 2016 | 174 | 0.500 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2015 | 48 | 0.490 |
Why?
|
| Calcium | 1 | 2017 | 480 | 0.490 |
Why?
|
| Environmental Exposure | 3 | 2018 | 216 | 0.480 |
Why?
|
| Disease Progression | 6 | 2021 | 601 | 0.470 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 69 | 0.470 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 357 | 0.460 |
Why?
|
| ADAM Proteins | 3 | 2020 | 16 | 0.460 |
Why?
|
| Neutrophil Infiltration | 3 | 2016 | 27 | 0.460 |
Why?
|
| Anoikis | 1 | 2013 | 21 | 0.460 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 583 | 0.460 |
Why?
|
| Trachea | 4 | 2017 | 25 | 0.450 |
Why?
|
| Air Pollution | 2 | 2005 | 60 | 0.440 |
Why?
|
| Inflammation Mediators | 5 | 2016 | 123 | 0.430 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 610 | 0.420 |
Why?
|
| Cell Division | 5 | 2021 | 307 | 0.420 |
Why?
|
| Rolipram | 1 | 2011 | 1 | 0.390 |
Why?
|
| Macrophages, Alveolar | 6 | 2020 | 34 | 0.390 |
Why?
|
| Cell Nucleus | 2 | 2013 | 366 | 0.380 |
Why?
|
| Health Status Disparities | 2 | 2017 | 642 | 0.380 |
Why?
|
| Logistic Models | 5 | 2018 | 923 | 0.370 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2016 | 149 | 0.370 |
Why?
|
| Interleukin-18 | 2 | 2007 | 15 | 0.360 |
Why?
|
| Cystic Fibrosis | 2 | 2012 | 18 | 0.350 |
Why?
|
| STAT1 Transcription Factor | 2 | 2007 | 35 | 0.340 |
Why?
|
| Respiratory Function Tests | 7 | 2024 | 55 | 0.340 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 7 | 0.330 |
Why?
|
| Respiratory Mechanics | 1 | 2008 | 27 | 0.330 |
Why?
|
| Phenotype | 8 | 2019 | 689 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 807 | 0.320 |
Why?
|
| Case-Control Studies | 8 | 2020 | 1130 | 0.320 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2005 | 16 | 0.320 |
Why?
|
| Carbon Monoxide | 3 | 2022 | 34 | 0.320 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 251 | 0.300 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 2019 | 5 | 0.290 |
Why?
|
| Comorbidity | 3 | 2018 | 623 | 0.290 |
Why?
|
| Organ Culture Techniques | 3 | 2018 | 103 | 0.290 |
Why?
|
| Inhalation Exposure | 6 | 2018 | 43 | 0.280 |
Why?
|
| Airway Obstruction | 1 | 2006 | 9 | 0.280 |
Why?
|
| Horse Diseases | 1 | 2006 | 8 | 0.270 |
Why?
|
| Bronchial Hyperreactivity | 4 | 2013 | 12 | 0.270 |
Why?
|
| Antigens, CD | 2 | 2018 | 121 | 0.270 |
Why?
|
| Signal Transduction | 7 | 2020 | 1908 | 0.270 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 219 | 0.260 |
Why?
|
| Pulmonary Alveoli | 4 | 2021 | 27 | 0.260 |
Why?
|
| Cell Count | 4 | 2015 | 135 | 0.260 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 39 | 0.250 |
Why?
|
| Nasal Mucosa | 1 | 2004 | 29 | 0.250 |
Why?
|
| Rats, Inbred BN | 5 | 2008 | 21 | 0.240 |
Why?
|
| Linear Models | 2 | 2016 | 275 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 885 | 0.240 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 159 | 0.230 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2016 | 4 | 0.230 |
Why?
|
| Chemokines | 3 | 2015 | 97 | 0.220 |
Why?
|
| Proteins | 2 | 2003 | 369 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 1039 | 0.220 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 92 | 0.220 |
Why?
|
| Sugar Alcohols | 1 | 2022 | 2 | 0.220 |
Why?
|
| Carbohydrates | 1 | 2022 | 29 | 0.210 |
Why?
|
| NF-kappa B | 4 | 2023 | 339 | 0.210 |
Why?
|
| Antiporters | 1 | 2022 | 10 | 0.210 |
Why?
|
| Exocrine Glands | 1 | 2002 | 3 | 0.210 |
Why?
|
| Virus Replication | 3 | 2023 | 278 | 0.210 |
Why?
|
| Genotype | 5 | 2015 | 730 | 0.210 |
Why?
|
| Dyspnea | 1 | 2022 | 18 | 0.210 |
Why?
|
| Odds Ratio | 3 | 2022 | 534 | 0.210 |
Why?
|
| Enzyme Activation | 2 | 2016 | 444 | 0.200 |
Why?
|
| Gene Silencing | 2 | 2013 | 151 | 0.200 |
Why?
|
| Interleukin-6 | 2 | 2002 | 153 | 0.200 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2019 | 22 | 0.200 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 307 | 0.200 |
Why?
|
| Protective Agents | 1 | 2021 | 25 | 0.200 |
Why?
|
| GTPase-Activating Proteins | 1 | 2021 | 29 | 0.200 |
Why?
|
| Lung Injury | 1 | 2021 | 15 | 0.190 |
Why?
|
| Transcription Factors | 2 | 2022 | 681 | 0.190 |
Why?
|
| Metformin | 1 | 2021 | 65 | 0.190 |
Why?
|
| Pulmonary Fibrosis | 2 | 2019 | 31 | 0.190 |
Why?
|
| Mice, Nude | 2 | 2016 | 337 | 0.180 |
Why?
|
| Species Specificity | 2 | 2015 | 245 | 0.180 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 2231 | 0.180 |
Why?
|
| Genetic Loci | 2 | 2019 | 90 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Ubiquitination | 2 | 2018 | 61 | 0.180 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2020 | 12 | 0.180 |
Why?
|
| Stem Cells | 1 | 2021 | 141 | 0.180 |
Why?
|
| Sphingolipids | 1 | 2020 | 13 | 0.180 |
Why?
|
| United States | 5 | 2023 | 4223 | 0.180 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 306 | 0.180 |
Why?
|
| Prevalence | 2 | 2022 | 1455 | 0.170 |
Why?
|
| Chronic Disease | 2 | 2014 | 484 | 0.170 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2019 | 14 | 0.170 |
Why?
|
| Behavior, Animal | 1 | 2001 | 314 | 0.170 |
Why?
|
| Markov Chains | 2 | 2016 | 35 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 400 | 0.170 |
Why?
|
| Metabolomics | 1 | 2019 | 81 | 0.170 |
Why?
|
| Th2 Cells | 3 | 2008 | 58 | 0.160 |
Why?
|
| Pancreatic Elastase | 1 | 2018 | 7 | 0.160 |
Why?
|
| Hospitalization | 1 | 2022 | 388 | 0.160 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2013 | 37 | 0.160 |
Why?
|
| Infant | 1 | 2022 | 1046 | 0.160 |
Why?
|
| Energy Metabolism | 1 | 2019 | 168 | 0.160 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2018 | 8 | 0.160 |
Why?
|
| Sex Characteristics | 2 | 2015 | 230 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2016 | 118 | 0.160 |
Why?
|
| Aerosols | 3 | 2011 | 48 | 0.150 |
Why?
|
| Gases | 1 | 2018 | 24 | 0.150 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 14 | 0.150 |
Why?
|
| Mice, Inbred C3H | 2 | 2015 | 84 | 0.150 |
Why?
|
| Health Status Indicators | 2 | 2018 | 75 | 0.150 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 23 | 0.150 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 34 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 623 | 0.150 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2015 | 85 | 0.150 |
Why?
|
| Aniline Compounds | 1 | 2017 | 23 | 0.150 |
Why?
|
| Air Pollution, Indoor | 1 | 2018 | 41 | 0.150 |
Why?
|
| Endothelium | 1 | 2017 | 31 | 0.150 |
Why?
|
| Mortality | 1 | 2018 | 145 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 360 | 0.150 |
Why?
|
| Models, Biological | 2 | 2013 | 677 | 0.150 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 27 | 0.150 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2016 | 18 | 0.150 |
Why?
|
| Dogs | 2 | 2016 | 149 | 0.140 |
Why?
|
| Mice, Mutant Strains | 2 | 2007 | 80 | 0.140 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 617 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2017 | 80 | 0.140 |
Why?
|
| Cell Membrane | 1 | 2019 | 381 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 214 | 0.140 |
Why?
|
| Haplotypes | 4 | 2015 | 182 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2017 | 116 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2017 | 195 | 0.140 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 22 | 0.140 |
Why?
|
| Ribonucleoproteins | 1 | 2016 | 29 | 0.140 |
Why?
|
| Chick Embryo | 1 | 2016 | 74 | 0.140 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 62 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 225 | 0.140 |
Why?
|
| Government Regulation | 1 | 2016 | 15 | 0.140 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 974 | 0.140 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 76 | 0.140 |
Why?
|
| Incidence | 1 | 2018 | 922 | 0.130 |
Why?
|
| Cytoplasm | 1 | 2016 | 143 | 0.130 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2015 | 22 | 0.130 |
Why?
|
| Maternal Exposure | 1 | 2015 | 33 | 0.130 |
Why?
|
| Lipoxins | 1 | 2015 | 2 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2015 | 7 | 0.130 |
Why?
|
| Macrophages | 2 | 2016 | 439 | 0.130 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 10 | 0.130 |
Why?
|
| Matrix Metalloproteinases | 1 | 2015 | 48 | 0.130 |
Why?
|
| Dinoprostone | 1 | 2015 | 63 | 0.130 |
Why?
|
| Cell Survival | 3 | 2019 | 864 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 84 | 0.120 |
Why?
|
| Cell Line | 2 | 2016 | 1354 | 0.120 |
Why?
|
| Peptides | 1 | 2017 | 320 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 186 | 0.120 |
Why?
|
| Kidney | 1 | 2017 | 337 | 0.120 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2011 | 859 | 0.120 |
Why?
|
| DNA Damage | 2 | 2014 | 352 | 0.120 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 1 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 104 | 0.120 |
Why?
|
| Age Factors | 2 | 2021 | 1033 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2019 | 1378 | 0.120 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 12 | 0.120 |
Why?
|
| Interleukin-8 | 1 | 2014 | 60 | 0.120 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 17 | 0.120 |
Why?
|
| Genetic Markers | 2 | 2011 | 142 | 0.120 |
Why?
|
| Overweight | 1 | 2016 | 247 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2012 | 626 | 0.120 |
Why?
|
| Cilia | 1 | 2013 | 27 | 0.120 |
Why?
|
| Macaca fascicularis | 3 | 2021 | 64 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2017 | 854 | 0.110 |
Why?
|
| Phosphorylation | 1 | 2016 | 928 | 0.110 |
Why?
|
| Butyric Acid | 1 | 2013 | 18 | 0.110 |
Why?
|
| Histone Deacetylase 1 | 1 | 2013 | 15 | 0.110 |
Why?
|
| Diet | 2 | 2017 | 801 | 0.110 |
Why?
|
| Public Health | 1 | 2017 | 372 | 0.110 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 56 | 0.110 |
Why?
|
| Base Sequence | 2 | 2006 | 997 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 32 | 0.110 |
Why?
|
| Acetylation | 1 | 2013 | 98 | 0.110 |
Why?
|
| Pedigree | 1 | 2013 | 79 | 0.110 |
Why?
|
| Child | 5 | 2024 | 3131 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2379 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 115 | 0.110 |
Why?
|
| Bezafibrate | 2 | 2003 | 4 | 0.110 |
Why?
|
| Protein Transport | 2 | 2019 | 302 | 0.110 |
Why?
|
| Genetics, Population | 1 | 2013 | 100 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 448 | 0.110 |
Why?
|
| Sarin | 2 | 2002 | 7 | 0.100 |
Why?
|
| Chemical Warfare Agents | 2 | 2002 | 13 | 0.100 |
Why?
|
| Acute Disease | 1 | 2012 | 147 | 0.100 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2011 | 2 | 0.100 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 70 | 0.100 |
Why?
|
| Fever | 2 | 2002 | 57 | 0.100 |
Why?
|
| Indians, North American | 1 | 2014 | 159 | 0.100 |
Why?
|
| Carcinogens | 2 | 2003 | 124 | 0.100 |
Why?
|
| Cell Differentiation | 3 | 2011 | 587 | 0.100 |
Why?
|
| Prognosis | 1 | 2014 | 739 | 0.100 |
Why?
|
| Body Weight | 3 | 2002 | 434 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1198 | 0.100 |
Why?
|
| Eosinophils | 3 | 2013 | 20 | 0.100 |
Why?
|
| Software | 1 | 2013 | 217 | 0.100 |
Why?
|
| Age Distribution | 1 | 2011 | 225 | 0.100 |
Why?
|
| Nicotine | 2 | 2016 | 257 | 0.090 |
Why?
|
| Horses | 2 | 2011 | 23 | 0.090 |
Why?
|
| Genes, p16 | 1 | 2010 | 9 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2016 | 513 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 201 | 0.090 |
Why?
|
| Alcian Blue | 2 | 2007 | 3 | 0.090 |
Why?
|
| Periodic Acid-Schiff Reaction | 2 | 2007 | 3 | 0.090 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 13 | 0.090 |
Why?
|
| Myeloid Cells | 1 | 2010 | 29 | 0.090 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2009 | 16 | 0.090 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2009 | 51 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2010 | 113 | 0.090 |
Why?
|
| Oxidative Stress | 4 | 2017 | 938 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 182 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 455 | 0.080 |
Why?
|
| Subcellular Fractions | 1 | 2009 | 77 | 0.080 |
Why?
|
| RNA, Catalytic | 1 | 2008 | 5 | 0.080 |
Why?
|
| Annexin A5 | 1 | 2008 | 26 | 0.080 |
Why?
|
| Cathepsin D | 1 | 2008 | 17 | 0.080 |
Why?
|
| Cathepsin B | 1 | 2008 | 26 | 0.080 |
Why?
|
| Protein Binding | 1 | 2012 | 972 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2015 | 195 | 0.080 |
Why?
|
| Muscle Cells | 1 | 2008 | 11 | 0.080 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2008 | 8 | 0.080 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 10 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 290 | 0.080 |
Why?
|
| Autopsy | 1 | 2008 | 43 | 0.080 |
Why?
|
| Hematoxylin | 1 | 2007 | 2 | 0.080 |
Why?
|
| Antioxidants | 1 | 2011 | 416 | 0.080 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2007 | 3 | 0.080 |
Why?
|
| Hemagglutinins | 1 | 2007 | 9 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2007 | 62 | 0.080 |
Why?
|
| Coloring Agents | 1 | 2007 | 51 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2024 | 1418 | 0.080 |
Why?
|
| Cytochromes c | 1 | 2007 | 53 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2007 | 141 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 898 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 208 | 0.070 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2006 | 2 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 181 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2006 | 16 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2006 | 92 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 269 | 0.070 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 50 | 0.070 |
Why?
|
| Southwestern United States | 1 | 2006 | 40 | 0.070 |
Why?
|
| Eosinophilia | 2 | 2002 | 18 | 0.070 |
Why?
|
| Recurrence | 1 | 2006 | 131 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2004 | 77 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2005 | 72 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 893 | 0.060 |
Why?
|
| Body Temperature | 2 | 2002 | 36 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 5363 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 78 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2004 | 47 | 0.060 |
Why?
|
| Reference Values | 1 | 2004 | 212 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 4 | 2013 | 661 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 191 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2004 | 87 | 0.060 |
Why?
|
| Young Adult | 3 | 2024 | 4268 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 107 | 0.060 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2003 | 3 | 0.060 |
Why?
|
| Ploidies | 1 | 2003 | 5 | 0.060 |
Why?
|
| Beryllium | 1 | 2003 | 5 | 0.060 |
Why?
|
| Nitrosamines | 1 | 2003 | 10 | 0.060 |
Why?
|
| Nucleoproteins | 1 | 2023 | 11 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 116 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 209 | 0.060 |
Why?
|
| CHO Cells | 1 | 2003 | 124 | 0.060 |
Why?
|
| Costa Rica | 2 | 2014 | 7 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 562 | 0.060 |
Why?
|
| P-Selectin | 1 | 2002 | 7 | 0.060 |
Why?
|
| Culture Techniques | 1 | 2002 | 24 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 238 | 0.050 |
Why?
|
| Dissection | 1 | 2002 | 12 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 356 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 935 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2021 | 1369 | 0.050 |
Why?
|
| Caspases | 1 | 2023 | 147 | 0.050 |
Why?
|
| Alpha-Globulins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Alleles | 2 | 2017 | 321 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2003 | 131 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 92 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 286 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 803 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2002 | 43 | 0.050 |
Why?
|
| Hydrocarbons | 1 | 2002 | 2 | 0.050 |
Why?
|
| Nitrogen Oxides | 1 | 2002 | 5 | 0.050 |
Why?
|
| Larynx | 1 | 2002 | 8 | 0.050 |
Why?
|
| Hypoxanthines | 1 | 2021 | 3 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2021 | 7 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2002 | 27 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 523 | 0.050 |
Why?
|
| Pigmentation | 1 | 2002 | 11 | 0.050 |
Why?
|
| Ozone | 1 | 2002 | 21 | 0.050 |
Why?
|
| Endotoxins | 1 | 2002 | 18 | 0.050 |
Why?
|
| Bronchitis | 1 | 2001 | 6 | 0.050 |
Why?
|
| Arachidonic Acid | 1 | 2001 | 35 | 0.050 |
Why?
|
| Equipment Design | 1 | 2002 | 124 | 0.050 |
Why?
|
| Heterozygote | 1 | 2001 | 93 | 0.050 |
Why?
|
| Persian Gulf Syndrome | 1 | 2001 | 2 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2001 | 39 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1568 | 0.050 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2003 | 162 | 0.050 |
Why?
|
| Receptors, Cholinergic | 1 | 2001 | 28 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 38 | 0.050 |
Why?
|
| Papio papio | 1 | 2021 | 1 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2001 | 53 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2001 | 86 | 0.050 |
Why?
|
| Vehicle Emissions | 1 | 2001 | 23 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2001 | 25 | 0.050 |
Why?
|
| Particle Size | 1 | 2002 | 215 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2002 | 174 | 0.050 |
Why?
|
| Spleen | 1 | 2001 | 199 | 0.050 |
Why?
|
| Respiratory System | 1 | 2021 | 28 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2018 | 2026 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2000 | 55 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 13 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2001 | 73 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2000 | 26 | 0.050 |
Why?
|
| Retinoids | 1 | 2000 | 28 | 0.050 |
Why?
|
| Kinetics | 1 | 2002 | 708 | 0.050 |
Why?
|
| DNA | 1 | 2003 | 574 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2015 | 435 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2001 | 150 | 0.050 |
Why?
|
| Eating | 1 | 2001 | 166 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 578 | 0.040 |
Why?
|
| Carbon | 1 | 2001 | 105 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2001 | 126 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2021 | 343 | 0.040 |
Why?
|
| Biomedical Research | 2 | 2017 | 400 | 0.040 |
Why?
|
| Cell Movement | 1 | 2003 | 571 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2001 | 233 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 44 | 0.040 |
Why?
|
| Motor Activity | 1 | 2001 | 418 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 311 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 539 | 0.040 |
Why?
|
| Household Products | 1 | 2018 | 2 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 325 | 0.040 |
Why?
|
| Aging | 1 | 2022 | 664 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 101 | 0.040 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2016 | 4 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 2016 | 35 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 31 | 0.040 |
Why?
|
| Animal Experimentation | 1 | 2016 | 2 | 0.040 |
Why?
|
| Mucociliary Clearance | 1 | 2016 | 5 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 22 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 461 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2015 | 15 | 0.030 |
Why?
|
| Keratins | 1 | 2015 | 25 | 0.030 |
Why?
|
| Pregnancy | 2 | 2015 | 1549 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2015 | 15 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2015 | 2 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 14 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 59 | 0.030 |
Why?
|
| Immunoglobulin E | 2 | 2008 | 55 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2014 | 3 | 0.030 |
Why?
|
| Fibrinolysin | 1 | 2014 | 8 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 162 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 661 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 267 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 1095 | 0.030 |
Why?
|
| Phenylbutyrates | 1 | 2013 | 5 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 237 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 72 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2013 | 32 | 0.030 |
Why?
|
| Cytosol | 1 | 2013 | 93 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 142 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 161 | 0.030 |
Why?
|
| Aldehydes | 1 | 2013 | 69 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 189 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 85 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 77 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 89 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 114 | 0.030 |
Why?
|
| Genome, Human | 1 | 2013 | 135 | 0.030 |
Why?
|
| DNA Ligases | 1 | 2011 | 13 | 0.030 |
Why?
|
| Nasal Obstruction | 1 | 2011 | 3 | 0.030 |
Why?
|
| Gelatinases | 1 | 2011 | 8 | 0.030 |
Why?
|
| Enzyme Precursors | 1 | 2011 | 14 | 0.030 |
Why?
|
| Clone Cells | 1 | 2011 | 47 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 47 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2011 | 45 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 409 | 0.020 |
Why?
|
| Culture Media | 1 | 2011 | 90 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 22 | 0.020 |
Why?
|
| International Cooperation | 1 | 2011 | 46 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 55 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 293 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 78 | 0.020 |
Why?
|
| Vegetables | 1 | 2011 | 147 | 0.020 |
Why?
|
| Pyridines | 1 | 2011 | 116 | 0.020 |
Why?
|
| Fruit | 1 | 2011 | 173 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 259 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 465 | 0.020 |
Why?
|
| Ambrosia | 1 | 2008 | 2 | 0.020 |
Why?
|
| Leukotriene C4 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2008 | 32 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 243 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 222 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2006 | 117 | 0.020 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2004 | 5 | 0.020 |
Why?
|
| Bronchiolitis, Viral | 1 | 2004 | 2 | 0.020 |
Why?
|
| Antibodies, Blocking | 1 | 2004 | 11 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 21 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2004 | 53 | 0.020 |
Why?
|
| Brain | 2 | 2002 | 1346 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2003 | 6 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 312 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 2002 | 18 | 0.010 |
Why?
|
| Turpentine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Acetylcholinesterase | 1 | 2002 | 55 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 35 | 0.010 |
Why?
|
| Solvents | 1 | 2002 | 99 | 0.010 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2001 | 1 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 2001 | 2 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 2001 | 5 | 0.010 |
Why?
|
| Chemokine CXCL2 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2001 | 50 | 0.010 |
Why?
|
| Autoradiography | 1 | 2001 | 36 | 0.010 |
Why?
|
| Peroxidase | 1 | 2001 | 49 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2001 | 7 | 0.010 |
Why?
|
| Airway Resistance | 1 | 2001 | 7 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2001 | 20 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2001 | 25 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 57 | 0.010 |
Why?
|
| Immune System | 1 | 2001 | 41 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2001 | 79 | 0.010 |
Why?
|
| Biological Availability | 1 | 2001 | 88 | 0.010 |
Why?
|
| Immunization | 1 | 2001 | 92 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 207 | 0.010 |
Why?
|
| Models, Animal | 1 | 2001 | 134 | 0.010 |
Why?
|
| Naphthalenes | 1 | 2000 | 38 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 236 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 78 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 433 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 502 | 0.010 |
Why?
|
| Liver | 1 | 2002 | 479 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 178 | 0.010 |
Why?
|